-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Alopexx, Inc. Prices IPO at $5.00 Per Share (ALPX)
Alopexx, Inc. Prices IPO at $5.00 Per Share (ALPX)
$Alopexx (ALPX.US)$ expects to raise $15 million in an initial public offering on the week of September 26th, IPO Scoop reports. The company will issue 3,000,000 shares at $5.00 per share.
The company has a market-cap of $39.2 million.
ThinkEquity acted as the underwriter for the IPO.
Alopexx, Inc. provided the following description of their company for its IPO: "We are a clinical stage biotechnology company developing novel immune therapeutics for the prevention, treatment and mitigation of bacterial, fungal and parasitic infections that express the antigenic target poly N-acetyl glucosamine (PNAG). That target has been found on an expanding number of pathogens. While the ultimate decision on the safety and efficacy of our therapeutics will be determined by the FDA and other health authorities, it is our management's assessment that the broad-spectrum potential of our therapeutics will allow them to be used for the prevention, treatment, and mitigation of a wide range of infections. In a first-in-man trial, our vaccine candidate, AV0328, has been shown to be well tolerated with no serious adverse events observed. It was noted to induce protective antibodies against all PNAG-expressing pathogens tested. We believe our vaccine's broad-spectrum potential will allow it to be used for the long-term prevention of a wide range of infections, including pneumococcal pneumonia, methicillin-resistant Staphylococcus aureus (MRSA), meningitis and sexually transmitted diseases. Similarly, our fully human monoclonal antibody, F598, which also targets PNAG, has been shown to be well tolerated and no serious adverse events were noted in phase 1 and pilot phase 2 trials. We believe it can provide immediate protection lasting 2-3 months. We seek to establish F598 as the standard of care for preventing and ameliorating gram-negative and gram-positive bacterial infections along with fungal infections by organisms that express PNAG in patients admitted to intensive care units (ICU). Utilization of these therapeutics also has potential applicability beyond infectious diseases, including treatment of neurological conditions and cognitive decline due to inflammation. Note: Net loss is for the year ended Dec. 31, 2021. **Note: As of June 30, 2022, we had an accumulated deficit of $5.99 million. Alopexx says that it has three officers and no employees before the IPO, according to the prospectus. (Note: Alopexx, Inc. increased the size of its IPO to 3.0 million shares, up from 2.5 million shares, and cut the price to $5.00, the bottom of its previous $5.00-to-$7.00 range, to raise $15 million (same estimate as before), according to an S-1/A filing dated Sept. 6, 2022. Alopexx disclosed its IPO terms – 2.5 million shares at $5.00 to $7.00 to raise $15 million – in an S-1/A filing dated Aug. 24, 2022. Alopexx filed an S-1/A dated April 20, 2022, disclosing that its proposed stock symbol is "ALPX". On March 4, 2022, Alopexx filed its S-1. The company filed confidential IPO documents with the SEC on Jan. 7, 2022.) ".
Alopexx, Inc. was founded in 2006 and has 0 employees. The company is located at 186 Alewife Brook Pkwy #1068 Cambridge, Massachusetts 02138 and can be reached via phone at (617) 780-1598
$Alopexx (ALPX.US)$ expects to raise $15 million in an initial public offering on the week of September 26th, IPO Scoop reports. The company will issue 3,000,000 shares at $5.00 per share.
$Alopexx (ALPX.US)$IPO Scoop报道,预计将在9月26日当周的首次公开募股中筹集1500万美元。该公司将以每股5.00美元的价格发行300万股股票。
The company has a market-cap of $39.2 million.
该公司的市值为3920万美元。
ThinkEquity acted as the underwriter for the IPO.
ThinkeQuity担任了首次公开募股的承销商。
Alopexx, Inc. provided the following description of their company for its IPO: "We are a clinical stage biotechnology company developing novel immune therapeutics for the prevention, treatment and mitigation of bacterial, fungal and parasitic infections that express the antigenic target poly N-acetyl glucosamine (PNAG). That target has been found on an expanding number of pathogens. While the ultimate decision on the safety and efficacy of our therapeutics will be determined by the FDA and other health authorities, it is our management's assessment that the broad-spectrum potential of our therapeutics will allow them to be used for the prevention, treatment, and mitigation of a wide range of infections. In a first-in-man trial, our vaccine candidate, AV0328, has been shown to be well tolerated with no serious adverse events observed. It was noted to induce protective antibodies against all PNAG-expressing pathogens tested. We believe our vaccine's broad-spectrum potential will allow it to be used for the long-term prevention of a wide range of infections, including pneumococcal pneumonia, methicillin-resistant Staphylococcus aureus (MRSA), meningitis and sexually transmitted diseases. Similarly, our fully human monoclonal antibody, F598, which also targets PNAG, has been shown to be well tolerated and no serious adverse events were noted in phase 1 and pilot phase 2 trials. We believe it can provide immediate protection lasting 2-3 months. We seek to establish F598 as the standard of care for preventing and ameliorating gram-negative and gram-positive bacterial infections along with fungal infections by organisms that express PNAG in patients admitted to intensive care units (ICU). Utilization of these therapeutics also has potential applicability beyond infectious diseases, including treatment of neurological conditions and cognitive decline due to inflammation. Note: Net loss is for the year ended Dec. 31, 2021. **Note: As of June 30, 2022, we had an accumulated deficit of $5.99 million. Alopexx says that it has three officers and no employees before the IPO, according to the prospectus. (Note: Alopexx, Inc. increased the size of its IPO to 3.0 million shares, up from 2.5 million shares, and cut the price to $5.00, the bottom of its previous $5.00-to-$7.00 range, to raise $15 million (same estimate as before), according to an S-1/A filing dated Sept. 6, 2022. Alopexx disclosed its IPO terms – 2.5 million shares at $5.00 to $7.00 to raise $15 million – in an S-1/A filing dated Aug. 24, 2022. Alopexx filed an S-1/A dated April 20, 2022, disclosing that its proposed stock symbol is "ALPX". On March 4, 2022, Alopexx filed its S-1. The company filed confidential IPO documents with the SEC on Jan. 7, 2022.) ".
Alopexx, Inc. 对其公司的首次公开募股提供了以下描述:“我们是一家临床阶段的生物技术公司,正在开发用于预防、治疗和缓解表达抗原靶聚N-乙酰氨基葡萄糖(PNAG)的细菌、真菌和寄生虫感染的新型免疫疗法。在越来越多的病原体上发现了该靶标。尽管我们疗法的安全性和有效性的最终决定将由美国食品药品管理局和其他卫生当局决定,但我们的管理层评估认为,我们的疗法的广谱潜力将使它们能够用于预防、治疗和缓解各种感染。在一项首次人体试验中,我们的候选疫苗 AV0328 已被证明具有良好的耐受性,没有观察到严重的不良事件。有人指出,它可以诱发针对所有测试的表达 pnAG 的病原体的保护性抗体。我们认为,我们的疫苗的广谱潜力将使其能够用于长期预防各种感染,包括肺炎球菌肺炎、耐甲氧西林金黄色葡萄球菌(MRSA)、脑膜炎和性传播疾病。同样,我们的全人源单克隆抗体F598(也靶向PNAG)已被证明具有良好的耐受性,在1期和试点2期试验中没有发现严重的不良事件。我们相信它可以提供持续 2-3 个月的即时保护。我们力求将F598确立为预防和改善革兰阴性和革兰氏阳性细菌感染以及重症监护病房(ICU)患者中表达 PNAG 的生物的真菌感染的护理标准。这些疗法的利用在传染病之外还有潜在的适用性,包括治疗神经系统疾病和炎症导致的认知能力下降。注意:净亏损是截至2021年12月31日的财年。**注意:截至2022年6月30日,我们的累计赤字为599万美元。根据招股说明书,Alopexx表示,在首次公开募股之前,它有三名高管,没有员工。(注意:根据2022年9月6日的S-1/A文件,Alopexx, Inc.将其首次公开募股规模从250万股增加到300万股,并将价格下调至5.00美元,这是之前的5.00至7.00美元区间的底部,筹集了1500万美元(与之前的估计相同)。Alopexx在2022年8月24日的一份S-1/A文件中披露了其首次公开募股条款——250万股,价格为5.00美元至7美元,筹集1500万美元。Alopexx 于 2022 年 4 月 20 日提交了 S-1/A,披露其拟议的股票代码为 “APX”。2022 年 3 月 4 日,Alopexx 提交了 S-1。该公司于 2022 年 1 月 7 日向美国证券交易委员会提交了机密的 IPO 文件。)”。
Alopexx, Inc. was founded in 2006 and has 0 employees. The company is located at 186 Alewife Brook Pkwy #1068 Cambridge, Massachusetts 02138 and can be reached via phone at (617) 780-1598
Alopexx, Inc. 成立于 2006 年,拥有 0 名员工。该公司位于 186 Alewife Brook Pkwy #1068 马萨诸塞州剑桥 02138,可以通过电话 (617) 780-1598 与该公司联系
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧